Icaritin inhibits castration-resistant prostate cancer via RhoB-mediated Akt signaling
Pathology - Research and Practice · 2026-07 · 283 · 156476
DOI: 10.1016/j.prp.2026.156476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026-07. Verfasst von Chen Hui und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Key Laboratory for Translational Cancer Research of Chinese Medicine, Intern…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Signal Transduction, Flavonoids, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 18 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Current therapeutic regimens for castration-resistant prostate cancer (CRPC) are plagued by multiple limitations. RhoB has emerged as a promising molecular target for prostate cancer (PCa) therapy. Icaritin, a bioactive prenylated flavonoid isolated from Epimedii Folium, exhibits potent antitumor and osteogenic properties. However, the anti-CRPC efficacy of icaritin and its underlying molecular mechanisms remain incompletely elucidated. Herein, we evaluated the anti-CRPC potential of icaritin and investigated the involvement of RhoB signaling. Results demonstrated that icaritin significantly suppressed the viability, proliferation, and clonogenic capacity of CRPC cells. Furthermore, in an RM-1 xenograft model, icaritin inhibited tumor growth and reduced serum levels of prostate-specific antigen (PSA) and testosterone. Integrated RNA-seq analysis and The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) dataset identified RhoB as a candidate therapeutic target in CRPC. Subsequent mechanistic investigations revealed that icaritin inhibits CRPC progression by modulating RhoB-mediated Akt signaling. Collectively, these findings indicate that the anti-CRPC activity of icaritin is at least partially mediated through the RhoB/Akt signaling, providing a pharmacological basis for the further development of icaritin as a potential therapeutic agent against CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Key Laboratory for Translational Cancer Research of Chinese Medicine, International Institute for Translational Chinese Medicine, Guangzhou Univer…
- Shenzhen Bao'an Hospital of Traditional Chinese Medicine, The Seventh School of Clinical Medicine, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China. Electronic address: 20212110033@stu.gzucm.edu.cn.
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. Electronic address: rain11125@163.com.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- Sanming Project of Medicine in Shenzhen
Zitieren
APA
Hui, C., Fan, Z., Yingyao, M., Shu, G., & Tao, S. (2026). Icaritin inhibits castration-resistant prostate cancer via RhoB-mediated Akt signaling. Pathology - Research and Practice, 283, 156476. https://doi.org/10.1016/j.prp.2026.156476
Vancouver
Hui C, Fan Z, Yingyao M, Shu G, Tao S. Icaritin inhibits castration-resistant prostate cancer via RhoB-mediated Akt signaling. Pathology - Research and Practice. 2026;283:156476. doi:10.1016/j.prp.2026.156476
BibTeX
@article{Hui2026,
author = {Hui, Chen and Fan, Zhang and Yingyao, Ma and Shu, Gan and Tao, Su},
title = {Icaritin inhibits castration-resistant prostate cancer via RhoB-mediated Akt signaling},
journal = {Pathology - Research and Practice},
year = {2026},
volume = {283},
pages = {156476},
doi = {10.1016/j.prp.2026.156476}
}
EUVIMED